{"id":956992,"date":"2026-04-30T18:05:03","date_gmt":"2026-04-30T22:05:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/yd-bio-limited-reports-full-year-2025-financial-results\/"},"modified":"2026-04-30T18:05:03","modified_gmt":"2026-04-30T22:05:03","slug":"yd-bio-limited-reports-full-year-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/yd-bio-limited-reports-full-year-2025-financial-results\/","title":{"rendered":"YD Bio Limited Reports Full Year 2025 Financial Results"},"content":{"rendered":"
\n

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (\u201cYD Bio\u201d or the \u201cCompany\u201d) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025.<\/p>\n

\n Management Commentary
<\/strong><\/strong>\u201c2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our balance sheet. Furthermore, we achieved a 17% increase in net revenue, driven predominantly by expanded pharmaceutical sales volumes and strategic new product launches,\u201d said Dr. Ethan Shen, Chairman and CEO of YD Bio. \u201cWe ended the year well-capitalized with approximately $6.0 million in cash and cash equivalents, which we believe positions us to securely meet our operating obligations in 2026 and aggressively pursue our clinical milestones.\u201d<\/p>\n

\u201cDuring the past year, we consciously increased our research and development expenditures by approximately $1.1 million to secure essential licensed patents and technological know-how, and we restructured our sales mix to rapidly scale our commercial footprint. These foundational investments in our clinical service infrastructure and diagnostics platform are designed to support robust growth across multiple regulated healthcare segments.\u201d<\/p>\n

\u201cLooking ahead, our strategic focus for 2026 is to aggressively advance our proprietary assets from validation toward expanded regulatory and commercial execution. We have already achieved certain milestones in our therapeutics pipeline by completing comprehensive Chemistry, Manufacturing, and Controls (CMC) development and filing Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) for our Limbal Stem Cell (LSC) platform and derived exosome products. This paves the way for us to submit Investigational New Drug (IND) applications to the FDA for both Dry Eye Disease and Age-Related Macular Degeneration in 2026. Concurrently, we are advancing our OkaiDx\u2122 Pancreatic Cancer Early Detection Program toward an FDA Q-Submission to discuss potential Breakthrough Device eligibility and building upon our EG Telehealth Platform, which was recently launched in March 2026 to support diagnostic service delivery across the United States.\u201d<\/p>\n

\u201cFinally, our vision to become an integrated, multi-vertical healthcare platform is being aggressively pursued through strategic M&A activity. For example, the previously announced merger with EG BioMed aims to seamlessly integrate DNA methylation-driven artificial intelligence platforms into our oncology programs,\u201d said Dr. Shen.<\/p>\n

\n YD Bio’s Full Year 2025 Financial Results
<\/strong><\/strong>Through the Company\u2019s combined diagnostics platform, clinical service infrastructure, and healthcare commercialization capabilities, YD Bio seeks to develop a scalable operating model designed to support growth across multiple regulated healthcare segments. The following table presents selected summarized financial information taken from YD Bio\u2019s consolidated statements of operations for the year ended December 31, 2025 and 2024.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n In thousands USD, except percentage\u00a0data, differences due to rounding<\/em>\n <\/td>\n\u00a0<\/td>\n\n For the years ended December 31,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Variance %<\/strong>\n <\/td>\n<\/tr>\n
Net Revenue<\/td>\n$<\/td>\n597<\/td>\n\u00a0<\/td>\n510<\/td>\n\u00a0<\/td>\n17<\/td>\n%<\/td>\n<\/tr>\n
Cost of Revenue<\/td>\n\u00a0<\/td>\n(429<\/td>\n)<\/td>\n(355<\/td>\n)<\/td>\n21<\/td>\n%<\/td>\n<\/tr>\n
Gross Profit<\/td>\n\u00a0<\/td>\n168<\/td>\n\u00a0<\/td>\n155<\/td>\n\u00a0<\/td>\n8<\/td>\n%<\/td>\n<\/tr>\n
General and Administrative Expenses<\/td>\n\u00a0<\/td>\n3,663<\/td>\n\u00a0<\/td>\n1,125<\/td>\n\u00a0<\/td>\n226<\/td>\n%<\/td>\n<\/tr>\n
Selling and Marketing Expenses<\/td>\n\u00a0<\/td>\n171<\/td>\n\u00a0<\/td>\n2<\/td>\n\u00a0<\/td>\n8,450<\/td>\n%<\/td>\n<\/tr>\n
Research and Development Expenses<\/td>\n\u00a0<\/td>\n1,602<\/td>\n\u00a0<\/td>\n491<\/td>\n\u00a0<\/td>\n226<\/td>\n%<\/td>\n<\/tr>\n
Impairment of expected credit loss<\/td>\n\u00a0<\/td>\n3<\/td>\n\u00a0<\/td>\n(1<\/td>\n)<\/td>\n400<\/td>\n%<\/td>\n<\/tr>\n
Total Operating Expenses<\/td>\n\u00a0<\/td>\n5,439<\/td>\n\u00a0<\/td>\n1,617<\/td>\n\u00a0<\/td>\n236<\/td>\n%<\/td>\n<\/tr>\n
Loss from Operations<\/td>\n\u00a0<\/td>\n(5,271<\/td>\n)<\/td>\n(1,462<\/td>\n)<\/td>\n261<\/td>\n%<\/td>\n<\/tr>\n
Net Loss<\/td>\n\u00a0<\/td>\n(8,310<\/td>\n)<\/td>\n(1,412<\/td>\n)<\/td>\n489<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Net Revenue
<\/strong><\/strong>Net revenue increased by $86,457 or 17% to $596,817 for the year ended December 31, 2025, compared to $510,360 for the year ended December 31, 2024. The top 5 individual products by revenue accounted for 41% of the total revenue during the period. The increase in revenue was primarily due to higher sales volumes and a shift in product mix toward lower-priced products, as reflected in the decrease in average selling price. Pharmaceutical sales, particularly Keytruda, which increased by approximately $48,598 driven by higher purchase volumes from key customers, along with new product launches, were the primary growth drivers. This growth was partially offset by decreased medical product sales, primarily due to the discontinuation of certain products and reduced orders for PVA eye cleansing tablets as a key customer adjusted its procurement strategy based on end-market feedback. Overall, the revenue change reflects a structural shift from higher-priced medical products toward pharmaceuticals and other lower-priced offerings.<\/p>\n

Top five individual products by revenue for the year ended December 31, 2025:<\/p>\n\n\n\n\n\n\n\n\n\n
\n Product<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Revenue<\/strong>\n <\/td>\n<\/tr>\n
Keytruda Injection (Drugs)<\/td>\n$<\/td>\n133,138<\/td>\n<\/tr>\n
HQ Revitalizing and Renewing Tencel Mask (Beauty Products)<\/td>\n\u00a0<\/td>\n36,749<\/td>\n<\/tr>\n
Exolens Hioxifilcon (Contact lenses)<\/td>\n\u00a0<\/td>\n35,000<\/td>\n<\/tr>\n
Mounjaro Pen (Drugs)<\/td>\n\u00a0<\/td>\n22,025<\/td>\n<\/tr>\n
12-Lead Electrocardiograph (Medical and related products)<\/td>\n\u00a0<\/td>\n20,416<\/td>\n<\/tr>\n
\n Subtotal<\/strong>\n <\/td>\n\n $<\/strong>\n <\/td>\n\n 247,328<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Top five individual products by revenue for the year ended December 31, 2024:<\/p>\n\n\n\n\n\n\n\n\n\n
\n Product<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Revenue<\/strong>\n <\/td>\n<\/tr>\n
PVA Eye Cleansing Wipes (Medical and related products)<\/td>\n$<\/td>\n97,512<\/td>\n<\/tr>\n
Keytruda injection (Drugs)<\/td>\n\u00a0<\/td>\n84,540<\/td>\n<\/tr>\n
Immune Defense Proteins (Nutritional products)<\/td>\n\u00a0<\/td>\n33,613<\/td>\n<\/tr>\n
Fluorescence Cell Counter and Viability Analyzer (Medical and related products)<\/td>\n\u00a0<\/td>\n23,177<\/td>\n<\/tr>\n
Faslodex solution for injection (Drugs)<\/td>\n\u00a0<\/td>\n21,127<\/td>\n<\/tr>\n
\n Subtotal<\/strong>\n <\/td>\n\n $<\/strong>\n <\/td>\n\n 259,969<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Cost of Revenue
<\/strong><\/strong>Cost of revenue increased by $74,403 or 21% to $429,407 for the year ended December 31, 2025, compared to $355,004 for the year ended December 31, 2024. The cost of revenue consists primarily of purchase costs of products for resales. The increase in cost of revenue was higher than the increase of net revenue, which was primarily due to the change in sales mix to the products sold with a lower margin during the year. Specifically, the sales mix shifted from higher-margin medical products to drugs and medical peripherals with relatively lower margins, resulting in a decrease in overall gross margin. This impact was partially offset by lower procurement costs for certain products.<\/p>\n

\n Gross Profit
<\/strong><\/strong>Gross profit increased by $12,054 or 8% to $167,410 for the year ended December 31, 2025, compared to $155,356 for the year ended December 31, 2024. The year-to-year changes were primarily due to higher sales volumes and a shift in product mix toward lower-priced products.<\/p>\n

\n Operating Expenses
<\/strong><\/strong>For the year ended December 31, 2025, the Company\u2019s total operating expenses were approximately $5.4 million, reflecting an increase of $3.8 million compared to $1.6 million for the year ended December 31, 2024. The increase was mainly caused by the increase in professional and consultancy service fees related to the Company\u2019s expansion and restructuring costs of $1.1 million, the increase in research and development expenses by $1.1 million related to two licensed patents and know-how, and by the $1.3 million increase in staff costs from the expansion of the Company\u2019s business.<\/p>\n

\n Net Loss
<\/strong><\/strong>As a result of the foregoing, net loss for the year ended December 31, 2025 was $8.3 million compared to $1.4 million for the year ended December 31, 2024. The increase in net loss was mainly caused by the increase of change in fair value of warrant liabilities by $3.2 million, professional and consultancy service fees related to the Company expansion and restructuring by $1.1 million, research and development expenses by $1.1 million related to two licensed patents and know-how, and by the $1.3 million increase in staff costs from the expansion of the Company\u2019s business.<\/p>\n

\n Cash and Cash Equivalents
<\/strong><\/strong>As of December 31, 2025, YD Bio\u2019s cash was $6.0 million compared to $3.1 million as of December 31, 2024. This increase was primarily due to an equity raise of $13.9 million, offset by deferred offering cost of approximately $3.2 million, professional and consultancy services fees related to the Company expansion and restructuring of $1.5 million, research and development expenses of $1.1 million, payment for purchase of medical products and contact lenses of $1.9 million and prepayment for the purchase of office space and parking facilities of $1.5 million.<\/p>\n

\n YD Bio Major Developments and 2026 Outlook<\/strong>\n <\/p>\n

\n
\n Therapeutics and Limbal Stem Cell Platform<\/em>
\n <\/strong>\n <\/p>\n